Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Shares of Vera Therapeutics stock opened at $29.93 on Thursday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -11.47 and a beta of 1.11. The company has a quick ratio of ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab, but analysts believe the selloff was an overreaction. Atacicept is more disease-modifying, while ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

Vera Therapeutics BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...